Saniona AB
STO:SANION

Watchlist Manager
Saniona AB Logo
Saniona AB
STO:SANION
Watchlist
Price: 8.12 SEK 0.62% Market Closed
Market Cap: 903.3m SEK
Have any thoughts about
Saniona AB?
Write Note

Saniona AB
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Saniona AB
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Saniona AB
STO:SANION
Cash Interest Paid
kr12.9m
CAGR 3-Years
38%
CAGR 5-Years
95%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Cash Interest Paid
kr30m
CAGR 3-Years
16%
CAGR 5-Years
48%
CAGR 10-Years
77%
Zealand Pharma A/S
CSE:ZEAL
Cash Interest Paid
kr16m
CAGR 3-Years
58%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Cash Interest Paid
€15.6m
CAGR 3-Years
123%
CAGR 5-Years
91%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Cash Interest Paid
kr11.9m
CAGR 3-Years
-33%
CAGR 5-Years
-5%
CAGR 10-Years
-1%
Bioporto A/S
CSE:BIOPOR
Cash Interest Paid
-kr35k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Saniona AB
Glance View

Market Cap
903.3m SEK
Industry
Biotechnology

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

SANION Intrinsic Value
3.56 SEK
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Saniona AB's Cash Interest Paid?
Cash Interest Paid
12.9m SEK

Based on the financial report for Jun 30, 2024, Saniona AB's Cash Interest Paid amounts to 12.9m SEK.

What is Saniona AB's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 5Y
95%

Over the last year, the Cash Interest Paid growth was 15%. The average annual Cash Interest Paid growth rates for Saniona AB have been 38% over the past three years , 95% over the past five years .

Back to Top